UBS Group’s GSK PLC ADRhedged GSKH Stock Holding History

UBS Group’s Portfolio GSKH Stock Details GSKH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$222	Buy	+3	New	+$223	﹤0.01%	9985
2026 Q1	–	Sell	-65	Closed	-$4.43K	–	11490
2025 Q4	$4.43K	Sell	65 -35	-35%	-$2.32K	﹤0.01%	8838
2025 Q3	$6.08K	Sell	100 -33	-25%	-$1.81K	﹤0.01%	8808
2025 Q2	$6.99K	Buy	133 +100	+303%	+$5.35K	﹤0.01%	9047
2025 Q1	$1.84K	Buy	+33	New	+$1.78K	﹤0.01%	9437

Other funds holding GSKH

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

UBS Group's GSKH Position: Q2 2026 in Review

UBS Group opened a new position in GSK PLC ADRhedged (GSKH) in Q2 2026: 3 shares worth $222. The stake represents ﹤0.01% of the portfolio and ranks #9985 among its holdings. This is a return to the name: UBS Group previously reported a position in GSKH as recently as Q4 2025.

UBS Group first reported a position in GSKH in Q1 2025 and has held it in 5 quarters since. The position peaked at $6.99K in Q2 2025. 2 funds tracked by Wall St. Rank hold GSKH as of Q2 2026.

UBS Group held 3 shares of GSK PLC ADRhedged worth $222 as of Q2 2026.
GSK PLC ADRhedged was a new UBS Group position in Q2 2026.
GSK PLC ADRhedged made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9985 holding.
UBS Group first reported a position in GSK PLC ADRhedged in Q1 2025 and has held it in 5 quarters since.
UBS Group's GSK PLC ADRhedged position peaked at $6.99K in Q2 2025.
2 funds tracked by Wall St. Rank held GSK PLC ADRhedged as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.